AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38340349 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both immediate and delayed chemotherapy)
Number of subjects: 182
Study 38340586 — intervention group
Group type: EXPERIMENTAL
Intervention: External attention focus walking group (EAFWG)
Number of subjects: 102
Study 38340586 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attention focus walking group (IAFWG)
Number of subjects: 102
Study 38340586 — intervention group
Group type: COMPARATOR
Intervention: No attention focus walking group (NAFWG)
Number of subjects: 102
Study 38340586 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (EAFWG, IAFWG, NAFWG)
Number of subjects: 102
Study 38340677 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 133 mg
Number of subjects: 185
Study 38340677 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride 50 mg
Number of subjects: 185
Study 38340682 — intervention group
Group type: EXPERIMENTAL
Intervention: slDNA decrease during RT/TMZ
Number of subjects: 36
Study 38340682 — intervention group
Group type: EXPERIMENTAL
Intervention: slDNA detection at pre-RT
Number of subjects: 36
Study 38340682 — intervention group
Group type: COMPARATOR
Intervention: Whole cfDNA concentration
Number of subjects: 36
Study 38340682 — intervention group
Group type: COMPARATOR
Intervention: slDNA peak size
Number of subjects: 36
Study 38340682 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid exposition
Number of subjects: 36
Study 38340682 — intervention group
Group type: COMPARATOR
Intervention: Tumor volume
Number of subjects: 36
Study 38340723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher circulating MCPyV-specific CD8 T cell frequency before anti-PD-1 treatment
Number of subjects: 27
Study 38340723 — intervention group
Group type: COMPARATOR
Intervention: Intratumoral MCPyV-specific CD8 T cells
Number of subjects: 27
Study 38340811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 2 mg/day for 24 weeks
Number of subjects: 126
Study 38340811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 5 mg/day for 24 weeks
Number of subjects: 126
Study 38340811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 10 mg/day for 24 weeks
Number of subjects: 126
Study 38340811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 2 mg/day for 48 weeks
Number of subjects: 126
Study 38340811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 10 mg/day for 48 weeks
Number of subjects: 126
Study 38340811 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate monotherapy or delayed treatment
Number of subjects: 126
Study 38341145 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-gadolinium-enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 1064
Study 38341187 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD vaccine
Number of subjects: 270
Study 38341203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus SOX (S-1 and oxaliplatin)
Number of subjects: 54
Study 38341206 — intervention group
Group type: EXPERIMENTAL
Intervention: Different antiretroviral regimens
Number of subjects: 229
Study 38341207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED) - 2 low-energy diet days/week of 1000 kcal and 5 days/week of best NHS care healthy diet and physical activity advice
Number of subjects: 48
Study 38341207 — intervention group
Group type: COMPARATOR
Intervention: Best NHS care - 7 days/week until delivery of their baby
Number of subjects: 48
Study 38341207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED)
Number of subjects: 48
Study 38341207 — intervention group
Group type: COMPARATOR
Intervention: Best NHS care
Number of subjects: 48
Study 38341525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block (TTMPB) with 20 ml of 0.25% bupivacaine on each side
Number of subjects: 80
Study 38341525 — intervention group
Group type: COMPARATOR
Intervention: Pecto-intercostal fascial block (PIFB) with 20 ml of 0.25% bupivacaine on each side
Number of subjects: 80
Study 38341528 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus nutritional supplementation (SQ-LNS)
Number of subjects: 480
Study 38341528 — intervention group
Group type: COMPARATOR
Intervention: Standard of care plus unconditional cash transfer
Number of subjects: 480
Study 38341528 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 480
Study 38341590 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Self-Harm app intervention
Number of subjects: 280
Study 38341590 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 280
Study 38341669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 354
Study 38341669 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 354
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔP) in sepsis patients
Number of subjects: 3356
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔP) in pneumonia patients
Number of subjects: 3356
Study 38341938 — intervention group
Group type: COMPARATOR
Intervention: Driving pressure (ΔP) in patients ventilated for other reasons
Number of subjects: 3356
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power (MP)
Number of subjects: 3356
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU mortality
Number of subjects: 3356
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 3356
Study 38341938 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ventilation
Number of subjects: 3356
Study 38342115 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg oral enobosarm daily
Number of subjects: 136
Study 38342115 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg oral enobosarm daily
Number of subjects: 136
Study 38342126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gepotidacin (1500 mg twice daily for 5 days)
Number of subjects: 1531
Study 38342126 — intervention group
Group type: COMPARATOR
Intervention: Oral nitrofurantoin (100 mg twice daily for 5 days)
Number of subjects: 1531
Study 38342126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Number of subjects: 1531
Study 38342126 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 1531
Study 38342371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (AH) using a 1,480 nm diode laser, removing approximately one-third of the zona pellucida.
Number of subjects: 698
Study 38342371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching).
Number of subjects: 698
Study 38342371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (AH)
Number of subjects: 698
Study 38342372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared seminal plasma
Number of subjects: 792
Study 38342372 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 792
Study 38342430 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy
Number of subjects: 1092
Study 38342430 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1092
Study 38342430 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy with adjuvant therapy
Number of subjects: 1092
Study 38342441 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 40 mg orally for 30 days
Number of subjects: 147
Study 38342441 — intervention group
Group type: EXPERIMENTAL
Intervention: A+Z (anakinra 100 mg subcutaneously for 14 days plus zinc sulfate 220 mg orally for 90 days)
Number of subjects: 147
Study 38342735 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention consisting of 10 weekly sessions including psychoeducation about depression, life areas and values assessment, activity scheduling, and self-monitoring of satisfaction and mood.
Number of subjects: 70
Study 38342735 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP) as a standard of care control intervention consisting of 10 weekly sessions of reassurance, guidance, encouragement, and support.
Number of subjects: 70
Study 38342735 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention
Number of subjects: 70
Study 38342823 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 37
Study 38342823 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study 38342986 — intervention group
Group type: EXPERIMENTAL
Intervention: Suaahara nutrition programme
Number of subjects: 2040
Study 38343073 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0
Study 38343073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38343144 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention group
Number of subjects: 68
Study 38343144 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) intervention group
Number of subjects: 68
Study 38343144 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 38343151 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax-azacitidine
Number of subjects: 431
Study 38343151 — intervention group
Group type: COMPARATOR
Intervention: placebo-azacitidine
Number of subjects: 431
Study 38343370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Coronary Roadmap (DCR) guidance
Number of subjects: 356
Study 38343370 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography guidance (Control)
Number of subjects: 356
Study 38343424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 38343424 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38343426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (subcutaneous)
Number of subjects: 23079
Study 38343431 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBRACE intervention
Number of subjects: 13
Study 38343583 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of RBC, HGB, and PLT in early and middle pregnancy
Number of subjects: 1027
Study 38343583 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of WBC in early pregnancy
Number of subjects: 1027
Study 38343583 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC, RBC, HGB, and PLT in early and middle pregnancy
Number of subjects: 1027
Study 38343583 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of hematological parameters in early and middle pregnancy
Number of subjects: 1027
Study 38343807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus of cholecalciferol (vitamin D)
Number of subjects: 0
Study 38343807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38343825 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 737
Study 38343825 — intervention group
Group type: EXPERIMENTAL
Intervention: Not on a ventilator
Number of subjects: 737
Study 38343825 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring data
Number of subjects: 737
Study 38343825 — intervention group
Group type: EXPERIMENTAL
Intervention: IH events
Number of subjects: 737
Study 38343833 — intervention group
Group type: EXPERIMENTAL
Intervention: BeWeL (45-minute virtual cultural talk)
Number of subjects: 370
Study 38343833 — intervention group
Group type: EXPERIMENTAL
Intervention: BeWeL plus motivational interviewing with social networks (60 minutes total)
Number of subjects: 370
Study 38343833 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 370
Study 38344045 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day)
Number of subjects: 3529
Study 38344130 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling up direct-acting antiviral (DAA) treatment in prisons by 44% for 10 years (2021-2030)
Number of subjects: 0
Study 38344130 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling up HCV treatment excluding DAA pharmaceutical costs
Number of subjects: 0
Study 38344130 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling up HCV testing and treatment in prisons
Number of subjects: 0
Study 38344130 — intervention group
Group type: COMPARATOR
Intervention: Status quo scenario (baseline levels of HCV treatment)
Number of subjects: 0
Study 38344178 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg-tolvaptan administered orally for 7 consecutive days
Number of subjects: 0
Study 38344203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 1
Study 38344232 — intervention group
Group type: EXPERIMENTAL
Intervention: Art-producing activities in a hybrid format (in-person and online) for 3 months on a weekly basis
Number of subjects: 126
Study 38344232 — intervention group
Group type: EXPERIMENTAL
Intervention: Art-producing activities in a hybrid format (in-person and online)
Number of subjects: 126
Study 38344236 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and substance addictions assessment using questionnaires, including PSQI for sleep quality and Ford questionnaire for insomnia.
Number of subjects: 500
Study 38344257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with Bupivacaine (DB group)
Number of subjects: 90
Study 38344257 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (B group)
Number of subjects: 90
Study 38344257 — intervention group
Group type: COMPARATOR
Intervention: Saline (S group)
Number of subjects: 90
Study 38344659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR)
Number of subjects: 272
Study 38344659 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative diabetic retinopathy (PDR)
Number of subjects: 272
Study 38344659 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of diabetic retinopathy (DR)
Number of subjects: 272
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with Targeted Inserts
Number of subjects: 18080
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Email (opened)
Number of subjects: 18080
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Email (clicked links)
Number of subjects: 18080
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Website (logging in)
Number of subjects: 18080
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Website (tracking)
Number of subjects: 18080
Study 38344760 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 18080
Study 38344820 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5047
Study 38344820 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine, glimepiride, sitagliptin
Number of subjects: 5047
Study 38344871 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDE-ACS at presentation
Number of subjects: 4105
Study 38344871 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDE-ACS at 1 hour
Number of subjects: 4105
Study 38344871 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDE-ACS at 2 hours
Number of subjects: 4105
Study 38344871 — intervention group
Group type: COMPARATOR
Intervention: ESC 0/1-hour pathway
Number of subjects: 4105
Study 38344871 — intervention group
Group type: COMPARATOR
Intervention: ESC 0/2-hour pathway
Number of subjects: 4105
Study 38344871 — intervention group
Group type: COMPARATOR
Intervention: High-STEACS pathway
Number of subjects: 4105
Study 38344891 — intervention group
Group type: EXPERIMENTAL
Intervention: Buloxibutid (C21) intra-arterial infusion at doses of 3, 10, 30, 100, and 200 μg/min
Number of subjects: 5
Study 38344891 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion at doses of 0.8-3.2 μg/min
Number of subjects: 5
Study 38345056 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory markers (Ro52, Scl-70, CN-1A, PM-Scl100, Sm, U2SnRNP A', La, DNA, Ro60, PL-7)
Number of subjects: 481
Study 38345056 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory markers
Number of subjects: 481
Study 38345071 — intervention group
Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 3973
Study 38345269 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, daratumumab, and dexamethasone
Number of subjects: 0
Study 38345269 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide plus bortezomib and dexamethasone
Number of subjects: 0
Study 38345269 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab plus pomalidomide and dexamethasone
Number of subjects: 0
Study 38345397 — intervention group
Group type: EXPERIMENTAL
Intervention: CB-011 (hypoimmunogenic, allogeneic anti-BCMA CAR T cell therapy)
Number of subjects: 0
Study 38345397 — intervention group
Group type: EXPERIMENTAL
Intervention: CB-011
Number of subjects: 0
Study 38345463 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehydrated collagenated bone gel (test group; n=10)
Number of subjects: 20
Study 38345463 — intervention group
Group type: COMPARATOR
Intervention: Collagenated cortico-cancellous heterologous bone mixture (control group; n=10)
Number of subjects: 20
Study 38345529 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil oral suspension (200 mg)
Number of subjects: 0
Study 38345529 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil oral suspension with food
Number of subjects: 0
Study 38345529 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil oral suspension with sweetener/flavor vehicle
Number of subjects: 0
Study 38345529 — intervention group
Group type: COMPARATOR
Intervention: Belumosudil oral tablet (reference)
Number of subjects: 0
Study 38345710 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-implant (slow-eluting implant)
Number of subjects: 590
Study 38345710 — intervention group
Group type: EXPERIMENTAL
Intervention: FE-implant (fast-eluting implant)
Number of subjects: 590
Study 38345710 — intervention group
Group type: COMPARATOR
Intervention: Timolol eye drops, 0.5%
Number of subjects: 590
Study 38345710 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-implant
Number of subjects: 590
Study 38345710 — intervention group
Group type: EXPERIMENTAL
Intervention: FE-implant
Number of subjects: 590
Study 38345710 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 590
Study 38345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery (BCS) without SNB
Number of subjects: 125
Study 38345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy compliance
Number of subjects: 125
Study 38345741 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 61
Study 38345741 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical treatment (OMT)
Number of subjects: 61
Study 38345793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention (Apoyo con Cariño) with 5 home visits from a bilingual, bicultural lay patient navigator
Number of subjects: 209
Study 38345793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention (Apoyo con Cariño)
Number of subjects: 209
Study 38345793 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 209
Study 38345818 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 1612
Study 38345818 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction
Number of subjects: 1612
Study 38345818 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitution strategy (if rolled out to all eldercare facilities in China)
Number of subjects: 1612
Study 38345843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach mobile app
Number of subjects: 400
Study 38345843 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 400
Study 38345845 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls with gamified rewards
Number of subjects: 0
Study 38345845 — intervention group
Group type: COMPARATOR
Intervention: No scheduled coaching calls with gamified rewards
Number of subjects: 0
Study 38345845 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls with fixed rewards
Number of subjects: 0
Study 38345845 — intervention group
Group type: COMPARATOR
Intervention: No scheduled coaching calls with fixed rewards
Number of subjects: 0
Study 38345934 — intervention group
Group type: EXPERIMENTAL
Intervention: CONEMO intervention
Number of subjects: 0
Study 38346025 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mailing to both the health plan patient and their prescribing physician (patient plus physician arm)
Number of subjects: 14442
Study 38346025 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mailing to prescribing physician only (physician only arm)
Number of subjects: 14442
Study 38346025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14442
Study 38346180 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based STEADI assessment
Number of subjects: 720
Study 38346180 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 720
Study 38346237 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange treatment
Number of subjects: 0
Study 38346237 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 38346307 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 302
Study 38346307 — intervention group
Group type: COMPARATOR
Intervention: Needle Fasciotomy
Number of subjects: 302
Study 38346307 — intervention group
Group type: COMPARATOR
Intervention: Collagenase Injection
Number of subjects: 302
Study 38346403 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital Mycoplasma genitalium infection
Number of subjects: 432
Study 38346403 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 432
Study 38346403 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black participants
Number of subjects: 432